Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Somatic Mutations and DNA Hypermethylation at Enhancers and Promoters Identify Distinct Subtypes within Lower-Risk Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4587.

https://doi.org/10.1182/blood-2023-180071

Published: 2023

Journal Articles

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome

James A. Poulter, Jason C. Collins, Catherine Cargo, Ruth M. De Tute, Paul Evans, Daniela Ospina Cardona, David T. Bowen, Joanna R. Cunnington, Elaine Baguley, Mark Quinn, Michael Green, Dennis McGonagle, David B. Beck, Achim Werner, Sinisa Savic

Blood (2021) 137 (26): 3676–3681.

https://doi.org/10.1182/blood.2020010286

Published: 2021

Includes: Supplemental data

Journal Articles

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Blood (2020) 136 (2): 157–170.

https://doi.org/10.1182/blood.2020004850

Published: 2020

Journal Articles

The Impact of Diabetes Mellitus As Comorbid Condition, in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)— a Study of the European Leukemianet-Based MDS (EUMDS) Registry

Blood (2017) 130 (Supplement 1): 4264.

https://doi.org/10.1182/blood.V130.Suppl_1.4264.4264

Published: 2017

Journal Articles

Impact of Treatment with Iron Chelation Therapy in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Blood (2017) 130 (Supplement 1): 425.

https://doi.org/10.1182/blood.V130.Suppl_1.425.425

Published: 2017

Journal Articles

Can We Diagnose MDS without Bone Marrow Examination? a Proposed EUMDS-Based Non-Invasive Diagnostic Model

Blood (2017) 130 (Supplement 1): 2975.

https://doi.org/10.1182/blood.V130.Suppl_1.2975.2975

Published: 2017

Journal Articles

Impact of Red Blood Cell Transfusion Intensity on Progression-Free Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS Registry

Blood (2017) 130 (Supplement 1): 1690.

https://doi.org/10.1182/blood.V130.Suppl_1.1690.1690

Published: 2017

Journal Articles

A Prognostic Classifier Based on Early Platelet Drop in Lower-Risk MDS. a Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry

Blood (2017) 130 (Supplement 1): 158.

https://doi.org/10.1182/blood.V130.Suppl_1.158.158

Published: 2017

Journal Articles

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression

Catherine A. Cargo, Nicola Rowbotham, Paul A. Evans, Sharon L. Barrans, David T. Bowen, Simon Crouch, Andrew S. Jack

Blood (2015) 126 (21): 2362–2365.

https://doi.org/10.1182/blood-2015-08-663237

Published: 2015

Includes: Supplemental data

Journal Articles

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Blood (2011) 118 (24): 6239–6246.

https://doi.org/10.1182/blood-2011-09-377275

Published: 2011

Includes: Supplemental data

Journal Articles

European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients.

T. M. de Witte, Alex Smith, Jackie Droste, Pierre Fenaux, Argyris Symeonidis, Eva Hellstrom-Lindberg, MD, PhD, Guillermo Sanz, Jaroslav Cermak, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Reinhard Stauder, MD, Odile Beyne Rauzy, David T. Bowen, MD

Blood (2009) 114 (22): 3811.

https://doi.org/10.1182/blood.V114.22.3811.3811

Published: 2009

Journal Articles

Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 “Pick a Winner” Comparison.

Nigel H. Russell, MD, Robert K Hills, Ann E. Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, DPhil, Mary Frances McMullin, John AL Yin, David T. Bowen, MD, A. Burnett, MD, FRCP

Blood (2009) 114 (22): 486.

https://doi.org/10.1182/blood.V114.22.486.486

Published: 2009

Journal Articles

Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome

Ken I. Mills, Alexander Kohlmann, P. Mickey Williams, Lothar Wieczorek, Wei-min Liu, Rachel Li, Wen Wei, David T. Bowen, Helmut Loeffler, Jesus M. Hernandez, Wolf-Karsten Hofmann, Torsten Haferlach

Blood (2009) 114 (5): 1063–1072.

https://doi.org/10.1182/blood-2008-10-187203

Published: 2009

Includes: Supplemental data

Journal Articles

Microarray Classification of Myelodysplastic Syndrome (MDS) Identifies Subgroups with Distinct Clinical Outcomes.

Ken I. Mills, PhD, Alex Kohlmann, Ph.D., Mickey Williams, Ph.D., Wei-Min Liu, Ph.D., Rachel Li, David T. Bowen, M.D., Helmut Loeffler, M.D., Jesus M. Hernandez, M.D., Wolf-Karsten Hofmann, M.D., Torsten Haferlach, M.D., Lothar Wieczirek, Ph.D.

Blood (2007) 110 (11): 2426.

https://doi.org/10.1182/blood.V110.11.2426.2426

Published: 2007

Journal Articles

Rimcazole - A Sigma Receptor Antagonist - As a Potential Novel Therapy for Acute Myeloid Leukemia and Myeloma.

Yogesh Upadhye, MRCP, Stephen Watt, Ph.D, Barbara A. Spruce, MRCP, Ph.D, David T. Bowen, FRCP, MD

Blood (2005) 106 (11): 2486.

https://doi.org/10.1182/blood.V106.11.2486.2486

Published: 2005

Journal Articles

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

David T. Bowen, Marion E. Frew, Robert Hills, Rosemary E. Gale, Keith Wheatley, Michael J. Groves, Stephen E. Langabeer, Panagiotis D. Kottaridis, Anthony V. Moorman, Alan K. Burnett, David C. Linch

Blood (2005) 106 (6): 2113–2119.

https://doi.org/10.1182/blood-2005-03-0867

Published: 2005

Journal Articles

Promoter Methylation of RASSFIA , SHP1 and SOCS1 Genes in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndromes (MDS).

M. Farid Johan, Anne C. Goodeve, David T. Bowen, John T. Reilly

Blood (2004) 104 (11): 2999.

https://doi.org/10.1182/blood.V104.11.2999.2999

Published: 2004

Journal Articles

Quality of Life and Economic Impact of Red Blood Cell (RBC) Transfusions on Patients with Myelodysplastic Syndromes (MDS).

S. Brechignac, E. Hellstrom-Lindberg, D. T. Bowen, T. M. DeWitte, M. Cazzola, P. Fenaux

Blood (2004) 104 (11): 4716.

https://doi.org/10.1182/blood.V104.11.4716.4716

Published: 2004

Journal Articles

Trisenox® (arsenic trioxide) in Patients with Myelodysplastic Syndromes (MDS): Preliminary Results of a Phase I/II Study.

Norbert Vey, MD, Francois Dreyfus, MD, Agnes Guerci, MD, Pierre Fenaux, MD, Herve Dombret, MD, Alan K. Burnett, MD, Andre Bosly, MD, Walter Feremans, MD, David T. Bowen, MD, Marja Heiskala, MD

Blood (2004) 104 (11): 1433.

https://doi.org/10.1182/blood.V104.11.1433.1433

Published: 2004

Journal Articles

CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication

David T. Bowen, Marion E. Frew, Sara Rollinson, Philippa L. Roddam, Ann Dring, Martyn T. Smith, Stephen E. Langabeer, Gareth J. Morgan

Blood (2003) 101 (7): 2770–2774.

https://doi.org/10.1182/blood-2002-01-0228

Published: 2003

NARROW

Somatic Mutations and DNA Hypermethylation at Enhancers and Promoters Identify Distinct Subtypes within Lower-Risk Myelodysplastic Syndromes

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

The Impact of Diabetes Mellitus As Comorbid Condition, in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)— a Study of the European Leukemianet-Based MDS (EUMDS) Registry

Impact of Treatment with Iron Chelation Therapy in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Can We Diagnose MDS without Bone Marrow Examination? a Proposed EUMDS-Based Non-Invasive Diagnostic Model

Impact of Red Blood Cell Transfusion Intensity on Progression-Free Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS Registry

A Prognostic Classifier Based on Early Platelet Drop in Lower-Risk MDS. a Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients.

Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 “Pick a Winner” Comparison.

Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome

Microarray Classification of Myelodysplastic Syndrome (MDS) Identifies Subgroups with Distinct Clinical Outcomes.

Rimcazole - A Sigma Receptor Antagonist - As a Potential Novel Therapy for Acute Myeloid Leukemia and Myeloma.

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

Promoter Methylation of RASSFIA , SHP1 and SOCS1 Genes in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndromes (MDS).

Quality of Life and Economic Impact of Red Blood Cell (RBC) Transfusions on Patients with Myelodysplastic Syndromes (MDS).

Trisenox® (arsenic trioxide) in Patients with Myelodysplastic Syndromes (MDS): Preliminary Results of a Phase I/II Study.

CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only